HomeTagsEverest Medicines Limited

Tag: Everest Medicines Limited

Medical

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (Everest Medicines China), has entered into two strategic...

Medical

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

Everest Medicines (HKG:1952) today announced that it has acquired an exclusive license with Visara, Inc. (Visara), a subsidiary of NovaBridge Biosciences (formally known as...

Medical

Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen Cancer...

Medical

Everest Medicines Announces 2025 Interim Results: ‘Dual-Engine’ Strategy Driving Strong Synergies Between Commercialization and R&D

On August 29, Everest Medicines (HKG: 1952) announced its interim results for the six months ended June 30, 2025. The Company’s total revenue for...

Medical

Everest Medicines’ New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access

Everest Medicines (HKG: 1952.HK, Everest) today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for...

Medical

Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan

Everest Medicines (HKG: 1952) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R). NEFECON(R) is indicated to...

Medical

NEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines Accelerates Accessibility and Capacity Efforts

Everest Medicines (HKG: 1952) today announced that the supplemental application for the production expansion of NEFECON® has been officially approved by China’s National Medical...

123 Page 2 of 3